Article

US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in NEWLY PUBLISHED


Digital Healthcare

Global Digital Health Investments Would Reach $10.3 B in 2018, Asia on the Rise: Medgenera’s Report

KEY POINTS Global digital health investment fundings (disclosed) is estimated to reach ~10.3 $ Billion in 2018. China and India ...

NEWLY PUBLISHED

Top Companies Leading the Rare Disease Drug Discovery (2018)

KEY POINTS Here are the six companies playing on the front foot in the segment of rare diseases drug discovery. ...

GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Liquid Biopsy: The Golden Cancer Diagnostic Test (an Industrial Review)

KEY POINTS The liquid biopsy market is forecasted to grow at a CAGR of 20.6 percent to reach over $3 ...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply